The FSHD Society is offering an online, on-demand CME-accredited masterclass on facioscapulohumeral muscular dystrophy (FSHD). This course is of interest to any physician and allied health professional who sees adult and pediatric neuromuscular patients.
This state-of-the-art, on-demand CME course for clinicians will present information on the latest in diagnosis, genetic counseling and testing, natural history, symptom management, and standards of care. This course will also provide a forum for thought leaders to share ideas, challenges and successes in delivering optimal care to people with FSHD. Those taking the course will learn about the current therapy development and clinical trial landscape and the emerging implications for care.
This CME course is available on-demand
through September 22, 2022
It can take nearly a decade for the average person with FSH muscular dystrophy to get a correct diagnosis. Once they are finally diagnosed accurately, a person may face an equally frustrating quest to find clinicians − doctors, physical therapists, pulmonologists, and other specialists −who fully understand FSHD and can help manage their symptoms.
There are more than 7,000 rare diseases, and most doctors will see at most a handful of FSHD patients, if any, in their career. But that is little consolation for patients. We must find ways to help clinicians learn to recognize FSHD symptoms and understand the best practices in caring for their patients with FSHD.
Additionally, we are now in the age of clinical trials for FSHD, and if individuals who are in a trial are not all receiving the same high standard of care, that could have negative impacts on a trial.
- Imagine if a subset of patients in a trial is receiving physical therapy and mental health counseling, while others are not.
- Or what if some patients have undetected breathing issues that are affecting their energy level?
Such disparities can have an impact on patients’ outcomes during a clinical trial and introduce “noise” that can make it harder to understand the effects of the FSHD drug that is being tested.
To meet this need, the FSHD Society produced an on-demand course taught by top FSHD experts, which doctors can take to earn credits that they need to maintain their license to practice medicine.
Patients, you can tell your doctors about the FSHD Masterclass. You can also write a letter using our CME-Dear-Doctor-letter-template.
Accreditation and Designation Statements and Disclosure Report
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the FSHD Society. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.
PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Dates: September 27, 2021 – September 26, 2022
View the Accreditation and Designation Statements with Disclosure Report with Financial Disclosures.